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Resistant hypertensionHypertension is a multifactorial disorder associated with increased inducible nitric oxide synthase (iNOS)
expression and activity. While genetic polymorphisms affect iNOS expression, it is not known whether iNOS
gene polymorphisms affect the susceptibility to hypertension and the responses to antihypertensive therapy. This
study aimed at assessing whether iNOS polymorphisms ((CCTTT)n, g.-1026C>A, and g.2087G>A) and haplotypes
are associated with hypertension and with responsiveness to drug therapy. We studied 115 well controlled hyper-
tensive patients (HTN), 82 hypertensive patients resistant to optimized antihypertensive therapy (RHTN), and 113
normotensive healthy subjects (NT). Genotypingswere carried out using real-timepolymerase chain reaction (PCR)
and PCR ampliﬁcation followed by capillary electrophoresis. The software PHASE 2.1 was used to estimate the
haplotype frequencies in each group. Variant genotypes (GA+AA) for the g.2087G>A polymorphism were more
commonly found in hypertensive patients (HTN+RHTN) than in normotensives (P=0.016; OR=2.05). We
found no associations between genotypes and responsiveness to therapy (P>0.05). The S-C-A haplotype was
more commonly found in hypertensive patients (HTN+RHTN) than in normotensives (P=0.014; OR=6.07).
Interestingly, this haplotype was more commonly found in the HTN group than in the RHTN group (P=0.012;
OR=0.14). Our ﬁndings indicate that the g.2087G>A polymorphism in the iNOS gene affects the susceptibility to
hypertension. Moreover, while the S-C-A haplotype is associated with hypertension, it is also associated with
responsiveness to antihypertensive therapy.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Hypertension is a multifactorial condition affecting approximately 1
billion subjects, and is responsible for more than 7 million deaths per
year worldwide (Chobanian et al., 2003). Althoughmost patients will re-
quire two ormore drugs to control blood pressure effectively (Chobanian
et al., 2003), blood pressure remains above 140/90 mm Hg in some indi-
viduals despite adherence to treatment with full doses of at least three
antihypertensive drugs, including a diuretic (Calhoun et al., 2008). This
condition, which is deﬁned as resistant hypertension, affects 5%–30% of
hypertensive individuals (Kaplan, 2005; Moser and Setaro, 2006) and is
usually associated with extensive target organ damage (Kaplan, 2005).
Moreover, a small proportion of patients with resistant hypertensionric oxide synthase; HTN, well
atients resistant to optimized
ssure monitoring; NT, normo-
tion.
, Faculty of Medicine of Ribeirao
9-900 Ribeirao Preto, SP, Brazil.
ahoo.com (J.E. Tanus-Santos).
vier OA license.never achieve blood pressure control despitemaximummedical therapy,
and this condition is deﬁned as refractory hypertension (Acelajado et al.,
2012).
Abnormalities in nitric oxide (NO) play an important role in the
pathophysiology of hypertension (Sandrim et al., 2006; Vaziri and
Rodriguez-Iturbe, 2006; Watson et al., 2008) and are related to resis-
tant hypertension (Yugar-Toledo et al., 2007). NO is synthesized from
L-arginine by at least three different nitric oxide synthases (NOS): neuro-
nal, endothelial and inducible NOS (Moncada and Higgs, 1993). While
neuronal and endothelial isoforms are constitutively expressed, the
inducible isoform (iNOS) is expressed especially in inﬂammatory condi-
tions (Geller et al., 1994; MacNaul and Hutchinson, 1993; Wong and
Billiar, 1995).
Increased oxidative stress contributes to the alterations found in
hypertension (Rodriguez-Iturbe et al., 2003; Watson et al., 2008).
In fact, excessive amounts of reactive oxygen species (ROS) have det-
rimental cardiovascular effects (Castro et al., 2009) that may result of
the reaction between superoxide (an important ROS) and NO forming
peroxynitrite, thus promoting nitrosative stress and endothelial dys-
function (Vaziri and Rodriguez-Iturbe, 2006; Xia and Zweier, 1997).
This reaction is favored by excessive amounts of iNOS-derived NO
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hypertension and vascular diseases (Chou et al., 1998; Hallemeesch
et al., 2003; Kibbe et al., 1999).
iNOS is encoded by iNOS gene and its expression or activity is
modiﬁed by inﬂammatory mediators, cytokines, transcription factors,
and genetic polymorphisms (Loscalzo and Welch, 1995; Pautz et al.,
2010). In this respect, three functional iNOS genetic polymorphisms
have been widely studied. The microsatellite (CCTTT)n and the
g.-1026C>A polymorphisms are located in the promoter region,
whereas the g.2087G>A polymorphism is located in exon 16. These
polymorphisms have been associated with different diseases affecting
the cardiovascular system (Amaral et al., 2012; Bagarolli et al., 2010;
de O. S. Mansur et al., 2012; Fu et al., 2009; Warpeha et al., 1999).
However no previous study has examined whether these three poly-
morphisms are associated with responsiveness to antihypertensive
therapy. Moreover, no previous study has examined whether iNOS
haplotypes are associated with hypertension and with responsiveness
to antihypertensive therapy.
In the present study, we assessed whether these three iNOS poly-
morphisms or iNOS haplotypes are associated with hypertension and
with responsiveness to antihypertensive therapy.
2. Materials and methods
2.1. Study population
This study was approved by the Institutional Review Board at the
Faculty of Medical Sciences, State University of Campinas (Campinas,
SP, Brazil), and each subject provided written informed consent. All par-
ticipants underwent a complete medical history, physical examination
and laboratory analysis. We recruited from our hospital outpatient clinic
115 well controlled hypertensive patients (HTN) and 82 hypertensive
patients who were resistant to optimized antihypertensive therapy
(RHTN), which were classiﬁed according to 2007 Guidelines for the
management of arterial hypertension (Mancia et al., 2007). All subjects
with systolic blood pressure >140 mm Hg and/or diastolic blood
pressure >90 mm Hg concurrent with use of three different anti-
hypertensive drugs (among them, a diuretic) in optimal doses with
adequate patient compliance to the treatment were considered RHTN
(Mancia et al., 2007).
The diagnosis of resistant hypertension requires a reliable ofﬁce
blood pressure measurement technique and ambulatory blood pressure
monitoring (ABPM) to conﬁrm persistently elevated blood pressure
levels (Calhoun et al., 2008). White coat hypertension was excluded by
ABPM (Calhoun et al., 2008). Pseudoresistance cases, including lack of
blood pressure control secondary to poor medication adherence, as
well as secondary forms of hypertension, were properly observed and
excluded from the study (de Souza et al., 2009). Patientswith current he-
patic or renal diseases were also excluded. All individuals were regularly
followed up during the ﬁrst six months for drug therapy optimization.
ABPM was used not only to exclude pseudoresistance to antihyperten-
sive treatment but also as an auxiliary method to characterize HTN and
RHTN patients. As a control group, we recruited 113 normotensive
healthy volunteers (NT) from the local population, genetically unrelated
to the patients included in the other study groups. Venous blood samples
were collected and genomic DNA was extracted from the cellular com-
ponent of 1 ml of whole blood through salting-out method and stored
at−20 °C until analyzed.
2.2. Genotyping for iNOS gene polymorphisms
Genotypes for the g.-1026C>A (rs2779249) and g.2087G>A
(rs2297518) polymorphisms were assessed by Taqman Allele Discrim-
ination Assays (Applied Biosystems, Foster City, CA, USA) using real-
time polymerase chain reaction (PCR). Primers and probes for the
g.-1026C>A polymorphism were customized as follows: primerforward 5′-GCCTCTCAAAGTGCTAGGATTACAA-3′, primer reverse 5′-
GGGAATACTGTATTTCAGGCATTATAAGGA-3′ and probes 5′-TAGCCAC
[A/C]ATGCCCG-3′ (de O. S. Mansur et al., 2012). Probes and primers
used in the genotyping of g.2087G>A were designed by Applied
Biosystems (assay ID C_11889257-10). PCR reactions were performed
in a total volume of 10 μl (5 ng of template DNA, 1× Taqman
Genotyping Master Mix and 1× Taqman Allele Discrimination Assay).
Thermal cycling was performed in standard conditions and ﬂuores-
cence was recorded by the StepOne Plus Real Time PCR equipment
(Applied Biosystems, Foster City, CA, USA). Results were analyzed
with manufacturer's software.
The (CCTTT)n alleles were determined using PCR ampliﬁcation
followed by capillary electrophoresis. Primers for this polymorphism
were customized as follows: primer forward 5′ [FAM]-ACCCCTGG
AAGCCTACAACTGCAT-3′ and primer reverse 5′-GCCACTGCACCCTAG
CCTGTCTCA-3′. Each reaction was prepared at a ﬁnal volume of
12 μl as follows: 1× buffer, 6.7 mM MgCl2, 1.5 mM dNTP, 0.2 μM of
each primer, 2.4 units of Taq DNA polymerase and 15 ng of genomic
DNA. The thermal cycling for this polymorphism consisted of an
initial denaturation at 94 °C for 5 min; 25 cycles of denaturation at
94 °C for 30 s, annealing at 69 °C for 30 s and extension at 72 °C,
followed by a ﬁnal extension step at 60 °C for 60 min. PCR products
were submitted to capillary electrophoresis at the ABI-Prism 3130
Genetic Analyzer (ABI PRISM/PE Biosystems, Foster City, CA, USA)
using GS 500 LIZ® (Applied Biosystems, Foster City, CA, USA) as size
standard. The fragment proﬁles were analyzed at the Genemapper v
4.0 software (Applied Biosystems, Foster City, CA, USA).
2.3. Haplotype inference
The Bayesian statistical-based program PHASE (version 2.1, http://
www.stat.washington.edu/stephens/software.html) was used to esti-
mate the haplotype frequencies in each group (Stephens et al., 2001).
The possible haplotypes including genetic variants for the iNOS polymor-
phisms studied (S or L for the (CCTTT)n microsatellite, g.-1026C>A and
g.2087G>A polymorphisms) were: H1 (LAA), H2 (LAG), H3 (LCA), H4
(LCG), H5 (SAA), H6 (SAG), H7 (SCA) and H8 (SCG). Haplotypes H3
(LCA) and H5 (SAA) were excluded from statistical analysis as their
frequency was b5% in all groups.
2.4. Statistical analysis
The clinical and laboratory characteristics of the studied groups
were compared by one-way analysis of variance (ANOVA) followed
by the Tukey's test (normally distributed data), or by Kruskall–Wallis
test. Categorical variables were compared by chi-square tests. The
distribution of genotypes for each polymorphism was assessed for
deviation from the Hardy–Weinberg equilibrium by chi-squared tests.
To increase statistical power, we classiﬁed the (CCTTT)n microsatellite
alleles as short (S group, when 8 to 11 repeats were found) or long
(L group, when 12 to 17 repeats were found). For the same reason, the
GA and AA genotypes for the g.2087G>A polymorphism were also
combined. All haplotypes with frequencies b5% were excluded from
the analysis. A P value b0.05 was considered statistically signiﬁcant.
Genotype and haplotype distributions were compared between
groups by multivariate logistic regressions. Linear regression analysis
and nonlinear ﬁtting routines were performed using the software JMP
5.0.1a (SAS Institute) to assess univariate relations between variables.
In addition, a bivariate analysis was also performed to assess the poten-
tial confounding inﬂuence of each covariate on the relation between
iNOS genotypes and haplotypes and hypertension or resistance to
hypertensive treatment. The variables of clinical importance were
then included in multiple logistic regression models. Hypertension
and resistance to antihypertensive therapy were considered as depen-
dent variables. iNOS genotypes/haplotypes, age, ethnicity, gender, and
body mass index were considered as independent variables.
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Fig. 1. Allelic distribution of the (CCTTT)n microsatellite in normotensive, hypertensive
and resistant hypertensive groups.NT: normotensive healthy subjects; HTN: hypertensive
patients who achieved target blood pressure; RHTN, hypertensive patients who were
resistant to optimized antihypertensive therapy. Distributions were compared by chi-
squared tests. NT vs HTN: P=0.147; NT vs RHTN: P=0.417; HTN vs RHTN: P=0.863.
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Table 1 summarizes the clinical and laboratory characteristics of
310 individuals enrolled in the study. As expected, RHTN patients
presented higher systolic and diastolic blood pressures compared with
HTN and NT (Pb0.05), whereas HTN and NT showed similar blood pres-
sures (Table 1). RHTN patients were under more antihypertensive drugs
than HTN patients (Pb0.05; Table 1). While NT, HTN and RHTN groups
showed similar age, sex, and HDL cholesterol (P>0.05; Table 1), RHTN
patients presented higher body mass index, total cholesterol, triglycer-
ides, and glucose levels, and lower LDL cholesterol as compared with
HTN and NT (Pb0.05; Table 1). RHTN and HTN groups presented lower
% of white subjects as compared with the NT group (Pb0.05; Table 1).
The distribution of genotypes for each polymorphism studied here
showed no deviation from Hardy–Weinberg equilibrium (P>0.05).
Fig. 1 shows the allele frequency distribution for the microsatellite
polymorphism in the three groups of subjects. No signiﬁcant differ-
ences were found between the three study groups (P>0.05; Fig. 1).
When genotype distributions in all hypertensive patients
(HTN+RHTN) were compared with those found in control subjects
(NT group) by multivariate logistic regression analysis (Table 2), the
variant genotypes (GA+AA) for the g.2087G>A polymorphism
were signiﬁcantly associated with hypertension (P=0.016; OR=
2.05; Table 2). No other differences in the genotypes distributions
were found (P>0.05; Table 2).
Table 3 shows the comparison of genotype distributions between
HTN and RHTN patients (by multivariate logistic regression analysis)
to examine whether iNOS polymorphisms affect the responsiveness
to antihypertensive therapy. No signiﬁcant associations between iNOS
genotypes and resistance to therapy were found (P>0.05; Table 3).
To improve genetic information, we studied iNOS haplotypes. Table 4
shows the comparison of iNOS haplotype distributions between NT and
all hypertensive patients (HTN+RHTN) by multivariate logistic regres-
sion analysis. Interestingly, the SCA haplotype was associated with
increased risk of hypertension (P=0.014; OR=6.07; Table 4). In line
with this result, Table 5 shows that the multivariate logistic regression
analysis indicated that this iNOS haplotype (SCA) was also associated
with responsiveness to antihypertensive therapy (lower risk of resistant
hypertension; P=0.012; OR=0.14; Table 5).
4. Discussion
The main ﬁndings of this study were that: (i) the variant genotypes
(GA+AA) for the g.2087G>A polymorphism and the haplotype SCA
weremore commonly found in the hypertensive patients (HTN+RHTN)Table 1
Clinical and laboratorial characteristics of study groups.
Parameters NT HTN RHTN
n 113 115 82
Male/female 44/69 52/62 27/54
Age (years) 50±9 52±12 52±10
Ethnicity (% White) 64 50⁎ 38⁎
BMI (kg/m2) 27.5±4.7 28.7±5.0 30.8±6.7⁎†
SBP (mm Hg) 131±18 132±13 157±12⁎†
DBP (mm Hg) 85±12 84±9 97±7⁎†
Total cholesterol (mg/dl) 182±34 192±31 206±44⁎†
HDL cholesterol (mg/dl) 50.9±10.5 48.0±17.0 46.5±12.6
LDL cholesterol (mg/dl) 137±47 129±41 111±32⁎†
Triglycerides (mg/dl) 127±63 131±57 151±52⁎†
Glucose (mg/dl) 88±11 92±31 102±36⁎†
Number of antihypertensive drugs – 1.45±0.81 3.55±0.83†
BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; NT,
normotensive healthy controls; HTN, hypertensive patients who achieved target blood
pressure; RHTN, hypertensive patients resistant to optimized antihypertensive therapy.
Data are expressed as mean±S.D., or absolute numbers, or relative frequencies.
⁎ Pb0.05 compared with NT group.
† Pb0.05 compared with HTN group.than in normotensive controls; (ii) the SCA haplotype was more
commonly found in the HTN group than in the RHTN group. Together,
these ﬁndings suggest that the g.2087G>A polymorphism affects the
susceptibility to hypertension, and that the SCA haplotype increases
the susceptibility to hypertension and the responsiveness to antihyper-
tensive therapy.
The g.2087G>A polymorphism causes an amino acid substitution
from serine to leucine, thus increasing iNOS activity and NO forma-
tion (Wang et al., 2006). Our ﬁndings showing association of variant
genotypes (GA+AA) with hypertension are in line with a previous
study which showed that the A allele for the g.2087G>A polymor-
phism is associated with preeclampsia, an important hypertensive
disorder of pregnancy (Amaral et al., 2012). These studies are consis-
tent with increased iNOS activity in individuals carrying the A allele
for this polymorphism, which could lead to excessive amounts of
NO and increased peroxynitrite formation promoting protein nitra-
tion, vascular dysfunction and hypertension (Cuzzocrea et al., 2004;
Hong et al., 2001; Linz et al., 2003; Ma et al., 2001; Suzuki et al., 2006).
Experimental evidence supports the idea that increased iNOS activity
contributes to hypertension (Chou et al., 1998; Hallemeesch et al., 2003;
Kibbe et al., 1999). Indeed, the iNOS inhibitor aminoguanidine attenuat-
ed the development of hypertension in spontaneously hypertensive rats
(Hong et al., 2000), possibly as a result of improved vascular function
associated with this drug (Tian et al., 2010). Interestingly, both studies
showed decreased vascular nitrotyrosine levels as a result of iNOS inhibi-
tion. Moreover, administration of selective iNOS inhibitors improved
cutaneous vasodilation in hypertensive humans (Smith et al., 2011).
Together, these studies support the idea that increased iNOS activityTable 2
Genotype frequencies in NT and hypertensive patients (HTN+RHTN).
Genotypes NT (n=113) Hypertensive
patients
(n=197)
P OR (CI)
g.-1026C>A CC 42 (0.37) 79 (0.40) – 1.00 (Reference)
CA 53 (0.47) 89 (0.45) 0.718 0.88 (0.43 to 1.76)
AA 18 (0.16) 29 (0.15) 0.883 0.93 (0.37 to 2.39)
g.2087G>A GG 90 (0.80) 135 (0.68) – 1.00 (Reference)
GA+AA 23 (0.20) 62 (0.32) 0.016 2.05 (1.16 to 3.75)
(CCTTT)n
Shortb12 LL 41 (0.36) 66 (0.34) – 1.00 (Reference)
SL 58 (0.51) 100 (0.50) 0.733 0.88 (0.43 to 1.78)
SS 14 (0.13) 31 (0.16) 0.695 1.22 (0.45 to 3.41)
NT, normotensive healthy controls; HTN, hypertensive patients who were well controlled;
RHTN, hypertensive who were resistant to optimized antihypertensive therapy.
OR, odds ratio; CI, 95% conﬁdence interval.
Pb0.05 was considered statistically signiﬁcant.
The genotype distributions were correct for age, gender, ethnicity, and body mass index.
Table 3
Genotype frequencies in HTN and RHTN groups.
Genotypes HTN
(n=115)
RHTN
(n=82)
P OR (CI)
g.-1026C>A CC 46 (0.40) 33 (0.40) – 1.00 (Reference)
CA 54 (0.47) 35 (0.43) 0.236 0.58 (0.24 to 1.42)
AA 15 (0.13) 14 (0.17) 0.309 1.83 (0.56 to 5.97)
g.2087G>A GG 74 (0.65) 61 (0.75) – 1.00 (Reference)
GA+AA 41 (0.35) 21 (0.25) 0.127 0.57 (0.28 to 1.16)
(CCTTT)n
Shortb12 LL 43 (0.38) 23 (0.28) – 1.00 (Reference)
SL 52 (0.45) 48 (0.59) 0.104 2.08 (0.87 to 5.11)
SS 20 (0.17) 11 (0.13) 0.411 0.60 (0.17 to 1.96)
NT, normotensive healthy controls; HTN, hypertensive patients who were well controlled;
RHTN, hypertensive who were resistant to optimized antihypertensive therapy.
OR, odds ratio; CI, 95% conﬁdence interval.
Pb0.05 was considered statistically signiﬁcant.
The genotype distributions were correct for age, gender, ethnicity, and body mass index.
Table 5
Haplotype frequencies in HTN and RHTN groups.
Haplotypes HTN
(n=230)
RHTN
(n=164)
P OR (CI)
H1 LAA 14 (0.06) 14 (0.09) 0.524 1.59 (0.37 to 6.68)
H2 LAG 58 (0.25) 35 (0.22) 0.499 0.72 (0.29 to 1.82)
H3 LCA 1 (0.00) 1 (0.00) – –
H4 LCG 65 (0.29) 44 (0.27) 0.896 1.06 (0.45 to 2.49)
H5 SAA 1 (0.00) 1 (0.00) – –
H6 SAG 11 (0.05) 13 (0.08) 0.096 3.70 (0.79 to 17.94)
H7 SCA 28 (0.12) 7 (0.04) 0.012 0.14 (0.03 to 0.60)
H8 SCG 52 (0.23) 49 (0.3) – 1.00 (Reference)
NT, normotensive healthy controls; HTN, hypertensive patients who were well controlled;
RHTN, hypertensive who were resistant to optimized antihypertensive therapy.
OR, odds ratio; CI, 95% conﬁdence interval.
H3 and H5 were excluded from statistical analysis due to their rare frequency.
Pb0.05 was considered statistically signiﬁcant.
The haplotype distributions were correct for age, gender, ethnicity, and body mass index.
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how the A allele for the 2087G>A polymorphism increases the risk for
hypertension.
While the g.-1026C>A polymorphism was associated with hyper-
tension in a Chinese population (Fu et al., 2009), and the A allele
for this polymorphism was associated with approximately ﬁvefold
increases in iNOS promoter transcriptional activity compared with
the C allele (Fu et al., 2009; Li et al., 2010), we found no signiﬁcant
associations in this study, at least when taking into consideration
the effects of this polymorphism alone. Similarly, although the long
alleles (>11 repeats) for the (CCTTT)n polymorphism have been
associated with increased iNOS expression compared with the short
alleles (Kaise et al., 2007), we found no effects in the present study.
Differences between populations or environmental factors may
explain differences between studies.
This is the ﬁrst study to investigate whether iNOS haplotypes are
associated with hypertension and with responsiveness to antihyper-
tensive drug therapy. Our results show that the SCA haplotype is
associated with hypertension. In fact, the long alleles for the (CCTTT)n
polymorphism, the A allele for the g.-1026C>A polymorphism, and
the A allele for the g.2087G>A polymorphism are associated with
increased iNOS expression (Fu et al., 2009; Kaise et al., 2007; Li et
al., 2010; Wang et al., 2006). However, the haplotype approach may
offer improved genetic information because it takes into consideration
the combined effects of different alleles (Sandrim et al., 2007, 2010a,
2010b). Thus, we suggest a possible interaction among the S, C, and A
alleles (SCAhaplotype), possibly increasing iNOS expression and increas-
ing the risk for hypertension through mechanisms suggested by experi-
mental studies (Chou et al., 1998; Hallemeesch et al., 2003; Kibbe et al.,
1999).Table 4
Haplotype frequencies in NT and hypertensive patients (HTN+RHTN).
Haplotypes NT
(n=226)
Hypertensive
patients (n=394)
P OR (CI)
H1 LAA 16 (0.07) 28 (0.07) 0.945 1.04 (0.32 to 3.69)
H2 LAG 59 (0.26) 93 (0.23) 0.103 0.54 (0.26 to 1.13)
H3 LCA 2 (0.01) 2 (0.01) – –
H4 LCG 63 (0.28) 109 (0.28) 0.247 0.66 (0.32 to 1.34)
H5 SAA 2 (0.01) 2 (0.01) – –
H6 SAG 12 (0.05) 24 (0.06) 0.876 0.90 (0.25 to 3.44)
H7 SCA 7 (0.03) 35 (0.09) 0.014 6.07 (1.57 to 29.27)
H8 SCG 65 (0.29) 101 (0.25) – 1.00 (Reference)
NT, normotensive healthy controls; HTN, hypertensive patients who were well controlled;
RHTN, hypertensive who were resistant to optimized antihypertensive therapy.
OR, odds ratio; CI, 95% conﬁdence interval.
H3 and H5 were excluded from statistical analysis due to their rare frequency.
Pb0.05 was considered statistically signiﬁcant.
The haplotype distributions were correct for age, gender, ethnicity, and body mass index.Although we found no signiﬁcant associations between iNOS
genotypes and responsiveness to antihypertensive drug therapy,
one particular iNOS haplotype was found in association with this
õcondition. Interestingly, this particular iNOS haplotype (SCA) was
also associated with susceptibility to hypertension. We could specu-
late that this association could be explained by antioxidant activity of
some antihypertensive drugs (Ceron et al., 2010; Gomes et al., 2006;
Martinez et al., 2006), which could improve antihypertensive responses
in a biological context of increased oxidative and nitrosative stress in
hypertensive patients carrying the SCA haplotype. It seems reasonable
to suspect that the iNOS haplotype that predisposes to hypertension by
promoting biochemical alterations can also enhance the responses
to drugs that inhibit these alterations. However, the biochemical and
molecular mechanisms underlying this suggestion remain to be proved.
In conclusion, our results indicate that the g.2087G>Apolymorphism
affects the susceptibility to hypertension. In addition, the iNOS SCA
haplotype predisposes to hypertension and affects the responsiveness
to antihypertensive therapy.
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